Cargando…
Formulation and Characterization of Pyrazinamide Polymeric Nanoparticles for Pulmonary Tuberculosis: Efficiency for Alveolar Macrophage Targeting
Pyrazinamide, a highly specific agent against Mycobacterium tuberculosis is used as first-line drug to treat tuberculosis. The current work aims to formulate polymeric nanoparticles based drug delivery system to sustain the release profile and reduce the dosing frequency of pyrazinamide. Further aim...
Autores principales: | Varma, J. N. Ravi, Kumar, T. Santosh, Prasanthi, B., Ratna, J. Vijaya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502139/ https://www.ncbi.nlm.nih.gov/pubmed/26180270 |
Ejemplares similares
-
Serum pyrazinamide concentrations in patients with pulmonary tuberculosis
por: Lucena, Stefania de Medeiros Araujo, et al.
Publicado: (2019) -
Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis
por: Werngren, Jim, et al.
Publicado: (2021) -
Pyrazinamide resistance in rifampicin discordant tuberculosis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2022) -
A Case of Delusional Disorder With Abuse of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol, the First-Line Anti-tuberculosis Therapy Drugs in India
por: Sathiyamoorthi, Sathiyanarayanan, et al.
Publicado: (2023) -
Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice
por: Almeida, Deepak V., et al.
Publicado: (2014)